Use of PAMP (proadrenomedullin N-terminal 20 peptide) and PAMP Inhibitors for the Treatment of Cancer, Cardiovascular Disease, a
Posted Nov 20 2012 7:00pm
Description of Invention: This technology details the use of PAMP or PAMP derivatives as a means to induce angiogenesis in tissue, as well as the use of PAMP inhibitors to inhibit angiogenesis.
PAMP (Proadrenomedullin N-terminal 20 peptide) is a 20 amino-acid molecule originating from the post-translational processing of pre-proadrenomedullin. PAMP is known as a potent hypotensive and vasodilatory agent; however, in addition to these properties, the inventors have discovered that PAMP also functions as a potent angiogenic factor. The inventors have also shown that an inhibitory fragment of PAMP, PAMP (12-20), is able to delay tumor growth in xenograft models of tumor progression. The ability to promote angiogenesis can be used as a means to increase vascularization in specific tissue areas or to treat patients with ischemic diseases. In contrast, the ability to inhibit this process can be used to limit growth of solid tumors and as a therapy for retinopathies, endometriosis, or arthritis.
PAMP and derivatives may be used as treatments for ischemic disease or coronary artery disease and to promote vascularization in graft tissues.
PAMP inhibitors may be used as treatments to limit growth of solid tumors or other angiogenesis-related disease.
PAMP exhibits a potent angiogenic potential at femtomolar concentrations, as opposed to nanomolar concentrations of other growth factors such as bFGF and VEGF.
PAMP and PAMP inhibitors provide a new mechanism for modulation of angiogenesis and treatment of angiogenesis-related diseases.
For Licensing Information Please Contact: Tara Kirby Ph.D. NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325, Rockville, MD 20852 United States Email: email@example.com Phone: 301-435-4426 Fax: 301-402-0220